World's Best Scientists 2026 revealed!
Howard L. Kaufman

Howard L. Kaufman

D-Index & Metrics

Immunology

D-Index
85
Citations
34317
World Ranking
1301
National Ranking
676

Medicine

D-Index
85
Citations
34572
World Ranking
14424
National Ranking
7298

Howard L. Kaufman publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Howard L. Kaufman sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 411 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Howard L. Kaufman D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Howard L. Kaufman sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 85 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Howard L. Kaufman is affiliated with Harvard University in the United States. Their research primarily focuses on Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions to Oncology, Immunology, Genetics, Molecular Biology, and Epidemiology.

Their scholarly work spans several key topics within biomedical research, including:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Virus-based gene therapy research
  • Nonmelanoma Skin Cancer Studies
  • Cutaneous Melanoma Detection and Management
  • Viral Infectious Diseases and Gene Expression in Insects

Among their recent publications are:

  • Therapy with oncolytic viruses: progress and challenges, 2023, Nature Reviews Clinical Oncology
  • Clinical landscape of oncolytic virus research in 2020, 2020, Journal for ImmunoTherapy of Cancer
  • Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma, 2022, New England Journal of Medicine
  • Immunotherapy for Non-melanoma Skin Cancer, 2021, Current Oncology Reports
  • Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19), 2020, Journal of Translational Medicine

They frequently collaborate with other researchers. Their notable co-authors include:

  • David M. Miller (23 collaborations)
  • Kevin S. Emerick (20 collaborations)
  • Sophia Z. Shalhout (19 collaborations)
  • Sailaja Battula (15 collaborations)
  • Ann W. Silk (11 collaborations)

Kaufman's publications often appear in specific venues with repeated contributions. The most frequent publication venues are:

  • Regular and Young Investigator Award Abstracts (14 publications)
  • Journal for ImmunoTherapy of Cancer (10 publications)
  • Journal of Cutaneous Oncology (9 publications)
  • Journal of Clinical Oncology (6 publications)
  • Cancer Research (5 publications)

Best Publications

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Oncolytic viruses: a new class of immunotherapy drugs

    Howard L. Kaufman;Frederick J. Kohlhapp;Andrew Zloza

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

    Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Integrating oncolytic viruses in combination cancer immunotherapy

    Praveen K. Bommareddy;Megha Shettigar;Howard L. Kaufman

  • Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.

    Howard L. Kaufman;Dae Won Kim;Gail DeRaffele;Josephine Mitcham

  • Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

    Igor Puzanov;Mohammed M. Milhem;David Minor;Omid Hamid

  • Therapy with oncolytic viruses: progress and challenges

    Unknown

  • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

    Robert H. I. Andtbacka;Frances Collichio;Kevin J. Harrington;Mark R. Middleton

  • Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

    Wenqian Zhang;Ying Yu;Falk Hertwig;Falk Hertwig;Jean Thierry-Mieg

  • Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma

    Giovanni C. Cesana;Gail DeRaffele;Seth Cohen;Dorota Moroziewicz

  • Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    Janice M. Mehnert;Anshuman Panda;Hua Zhong;Hua Zhong;Kim Hirshfield

  • Combination immunotherapy: a road map

    Patrick A. Ott;F. Stephen Hodi;Howard L. Kaufman;Jon M. Wigginton

  • Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

    Sandra P. D’Angelo;Jeffery Russell;Céleste Lebbé;Bartosz Chmielowski

  • Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.

    Hasan Rehman;Ann W. Silk;Michael P. Kane;Howard L. Kaufman

  • Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.

    Heidi Hörig;David S. Lee;William Conkright;Joe Divito

Frequent Co-Authors

David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Michael A. Morse
Michael A. Morse Duke University
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
John Nemunaitis
John Nemunaitis Gradalis (United States)
Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Merrick I. Ross
Merrick I. Ross The University of Texas MD Anderson Cancer Center
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Jeffrey Schlom
Jeffrey Schlom National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, exploring related healthcare degrees can open diverse career opportunities. Many students start with foundational nursing programs, such as online ABSN programs for non nurses. These accelerated courses are designed for individuals transitioning into nursing from other fields, providing a fast but thorough route into patient care and clinical practice.

When considering accelerated options, it’s important to understand that some come with more accessible admissions criteria. Resources highlighting the easiest accelerated nursing programs can help applicants identify programs that balance rigor with attainable entry requirements.

Beginning a nursing career might also involve enrolling in programs with simpler acceptance processes. For example, LPN schools easy to get into offer practical and practical nursing training that can serve as a stepping stone to advanced degrees in healthcare and immunology research.

Advancing further, some pursue specialized roles through nurse practitioner degrees. Exploring the what is the easiest NP program resources allows students to find programs that offer manageable entry into this expert level of nursing, which often intersects with immunology in clinical and research settings.

Best Scientists Citing Howard L. Kaufman

Trending Scientists

Recently Published Articles